8-K Announcements
3Material company update
Oct 29, 2025·SEC
Material company update
Oct 17, 2025·SEC
Material company update
Jun 6, 2025·SEC
Oaktree Acquisition Corp. III Life Sciences(OACCW)Earnings, Financials & Key Ratios
OACCW•NASDAQ
$0.92
3.1× P/E·Price updated Jul 6, 2026
SectorFinancial ServicesIndustrySPACs & Shell CompaniesSub-IndustryHealthcare and life sciences SPACs
AboutOaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.Show more
- EBITDA-$1M-119568800.0%
- Net Income$7M+273607.2%
- EPS (Diluted)0.30+453.5%
- ROE3.81%+272271.4%
OACCW Price & Volume
Oaktree Acquisition Corp. III Life Sciences (OACCW) stock price & volume — 10-year historical chart
Loading chart...
Trust Interest Masks Underlying Operational Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Liquidation and deal execution
Key Thesis Takeaways
- Oaktree Acquisition Corp.
- III Life Sciences functions as a pre-revenue shell entity where reported net income of $1.4M in 2026Q1 is entirely decoupled from operational performance, relying instead on interest from trust assets.
- The company faces significant pressure to finalize a biopharmaceutical business combination as its current ratio has compressed to 0.87, signaling tightening liquidity.
- Investors should monitor the risk of a suboptimal merger, as the entity's reliance on sponsor-backed debt and persistent administrative expenses may force a deal before the liquidation deadline.
Verdict Logic
the entity's reliance on non-operating interest income to report a $1.4M net income while burning $158.0K in operating cash flow suggests a high risk of capital erosion before a viable business combination is achieved.
OACCW Growth Metrics
Oaktree Acquisition Corp. III Life Sciences (OACCW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-0.3%
5 Years-0.3%
3 Years-0.3%
Last Year-0.6%
Peers Comparison
Key metrics vs top competitors for Oaktree Acquisition Corp. III Life Sciences (OACCW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.92 | $22.59M | 3.07 | — | — | 3.81% | — | |
| $18.90 | $3.58B | -11.74 | 53.44% | -2554.14% | -43.94% | — | |
| $3.96 | $1.77B | -2.75 | 26.92% | -844.46% | -54.32% | — | |
| $3.50 | $6.59M | -0.06 | — | — | -172.45% | — | |
| $10.46 | $151.49M | 47.55 | — | — | 12.93% | — | |
| $123.41 | $96.68B | 31.81 | 21.58% | 20.38% | 14.25% | — |
Compare OACCW vs Peers
Oaktree Acquisition Corp. III Life Sciences (OACCW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OACCW SEC Filings & Documents
Oaktree Acquisition Corp. III Life Sciences (OACCW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OACCW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OACCW Frequently Asked Questions
Oaktree Acquisition Corp. III Life Sciences (OACCW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is OACCW profitable?
Yes, Oaktree Acquisition Corp. III Life Sciences (OACCW) is profitable, generating $6.6M in net income for fiscal year 2025.
Dividend & Returns
What is OACCW's return on equity?
Oaktree Acquisition Corp. III Life Sciences (OACCW) has a return on equity (ROE) of 3.8%. This is below average, suggesting room for improvement.
What is Oaktree Acquisition Corp. III Life Sciences's free cash flow?
Oaktree Acquisition Corp. III Life Sciences (OACCW) had negative free cash flow of $0.4M in fiscal year 2025, likely due to heavy capital investments.